vs
AdvanSix Inc.（ASIX）与Pacira BioSciences, Inc.（PCRX）财务数据对比。点击上方公司名可切换其他公司
AdvanSix Inc.的季度营收约是Pacira BioSciences, Inc.的2.0倍（$359.9M vs $177.4M），Pacira BioSciences, Inc.净利率更高（1.6% vs -0.8%，领先2.4%），AdvanSix Inc.同比增速更快（9.4% vs 5.0%），过去两年AdvanSix Inc.的营收复合增速更高（3.4% vs -0.2%）
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
ASIX vs PCRX — 直观对比
营收规模更大
ASIX
是对方的2.0倍
$177.4M
营收增速更快
ASIX
高出4.4%
5.0%
净利率更高
PCRX
高出2.4%
-0.8%
两年增速更快
ASIX
近两年复合增速
-0.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $359.9M | $177.4M |
| 净利润 | $-2.8M | $2.9M |
| 毛利率 | 7.6% | — |
| 营业利润率 | -0.7% | 3.9% |
| 净利率 | -0.8% | 1.6% |
| 营收同比 | 9.4% | 5.0% |
| 净利润同比 | -892.9% | — |
| 每股收益（稀释后） | $-0.11 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASIXPCRX
| Q1 26 | — | $177.4M | ||
| Q4 25 | $359.9M | $196.9M | ||
| Q3 25 | $374.5M | $179.5M | ||
| Q2 25 | $410.0M | $181.1M | ||
| Q1 25 | $377.8M | $168.9M | ||
| Q4 24 | $329.1M | $187.3M | ||
| Q3 24 | $398.2M | $168.6M | ||
| Q2 24 | $453.5M | $178.0M |
净利润ASIXPCRX
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-2.8M | — | ||
| Q3 25 | $-2.6M | $5.4M | ||
| Q2 25 | $31.4M | $-4.8M | ||
| Q1 25 | $23.3M | $4.8M | ||
| Q4 24 | $352.0K | — | ||
| Q3 24 | $22.3M | $-143.5M | ||
| Q2 24 | $38.9M | $18.9M |
毛利率ASIXPCRX
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | 79.5% | ||
| Q3 25 | 6.8% | 80.9% | ||
| Q2 25 | 14.3% | 77.4% | ||
| Q1 25 | 14.2% | 79.7% | ||
| Q4 24 | 3.4% | 78.7% | ||
| Q3 24 | 14.4% | 76.9% | ||
| Q2 24 | 17.9% | 75.1% |
营业利润率ASIXPCRX
| Q1 26 | — | 3.9% | ||
| Q4 25 | -0.7% | 1.2% | ||
| Q3 25 | -0.9% | 3.5% | ||
| Q2 25 | 7.7% | 4.7% | ||
| Q1 25 | 7.7% | 1.2% | ||
| Q4 24 | -3.9% | 13.2% | ||
| Q3 24 | 7.5% | -82.8% | ||
| Q2 24 | 11.5% | 15.9% |
净利率ASIXPCRX
| Q1 26 | — | 1.6% | ||
| Q4 25 | -0.8% | — | ||
| Q3 25 | -0.7% | 3.0% | ||
| Q2 25 | 7.7% | -2.7% | ||
| Q1 25 | 6.2% | 2.8% | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 5.6% | -85.1% | ||
| Q2 24 | 8.6% | 10.6% |
每股收益（稀释后）ASIXPCRX
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.11 | $0.05 | ||
| Q3 25 | $-0.10 | $0.12 | ||
| Q2 25 | $1.15 | $-0.11 | ||
| Q1 25 | $0.86 | $0.10 | ||
| Q4 24 | $0.02 | $0.38 | ||
| Q3 24 | $0.82 | $-3.11 | ||
| Q2 24 | $1.43 | $0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.8M | $144.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $815.2M | $653.9M |
| 总资产 | $1.7B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASIXPCRX
| Q1 26 | — | $144.3M | ||
| Q4 25 | $19.8M | $238.4M | ||
| Q3 25 | $23.7M | $246.3M | ||
| Q2 25 | $18.4M | $445.9M | ||
| Q1 25 | $8.3M | $493.6M | ||
| Q4 24 | $19.6M | $484.6M | ||
| Q3 24 | $17.3M | $453.8M | ||
| Q2 24 | $12.1M | $404.2M |
总债务ASIXPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益ASIXPCRX
| Q1 26 | — | $653.9M | ||
| Q4 25 | $815.2M | $693.1M | ||
| Q3 25 | $818.2M | $727.2M | ||
| Q2 25 | $823.7M | $757.8M | ||
| Q1 25 | $794.4M | $798.5M | ||
| Q4 24 | $774.6M | $778.3M | ||
| Q3 24 | $766.4M | $749.6M | ||
| Q2 24 | $746.6M | $879.3M |
总资产ASIXPCRX
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.7B | $1.3B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.6B | $1.6B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.6B |
负债/权益比ASIXPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $63.7M | — |
| 自由现金流经营现金流 - 资本支出 | $36.1M | — |
| 自由现金流率自由现金流/营收 | 10.0% | — |
| 资本支出强度资本支出/营收 | 7.7% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $6.4M | — |
8季度趋势，按日历期对齐
经营现金流ASIXPCRX
| Q1 26 | — | — | ||
| Q4 25 | $63.7M | $43.7M | ||
| Q3 25 | $26.6M | $60.8M | ||
| Q2 25 | $21.1M | $12.0M | ||
| Q1 25 | $11.4M | $35.5M | ||
| Q4 24 | $64.2M | $33.1M | ||
| Q3 24 | $57.3M | $53.9M | ||
| Q2 24 | $50.2M | $53.2M |
自由现金流ASIXPCRX
| Q1 26 | — | — | ||
| Q4 25 | $36.1M | $43.5M | ||
| Q3 25 | $66.0K | $57.0M | ||
| Q2 25 | $-7.2M | $9.3M | ||
| Q1 25 | $-22.6M | $26.9M | ||
| Q4 24 | $29.8M | $31.0M | ||
| Q3 24 | $26.8M | $49.8M | ||
| Q2 24 | $16.7M | $51.6M |
自由现金流率ASIXPCRX
| Q1 26 | — | — | ||
| Q4 25 | 10.0% | 22.1% | ||
| Q3 25 | 0.0% | 31.7% | ||
| Q2 25 | -1.7% | 5.1% | ||
| Q1 25 | -6.0% | 15.9% | ||
| Q4 24 | 9.1% | 16.6% | ||
| Q3 24 | 6.7% | 29.6% | ||
| Q2 24 | 3.7% | 29.0% |
资本支出强度ASIXPCRX
| Q1 26 | — | — | ||
| Q4 25 | 7.7% | 0.1% | ||
| Q3 25 | 7.1% | 2.2% | ||
| Q2 25 | 6.9% | 1.5% | ||
| Q1 25 | 9.0% | 5.1% | ||
| Q4 24 | 10.4% | 1.1% | ||
| Q3 24 | 7.7% | 2.4% | ||
| Q2 24 | 7.4% | 0.9% |
现金转化率ASIXPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.49× | 7.37× | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | 2.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
